Drugs / Maridebart Cafraglutide
Maridebart Cafraglutide
Trials 22
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT07832799 | Oct 2026 → Mar 2027 expected | obesity disorder | Amgen | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07523711 | Apr → Nov 2026 expected | obesity disorder | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07313761 | Dec 2025 → Jun 2026 | — | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07229157 | Oct 2025 → Aug 2026 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07226778 | Oct 2025 → May 2026 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT07160257 | Aug 2025 → Nov 2026 expected | type 2 diabetes mellitus | Amgen | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06352892 | Apr → Aug 2024 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT04478708 | Aug 2020 → Nov 2022 | obesity disorder | Amgen | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT07441252 | Mar 2026 → Aug 2027 expected | NAFLD1 | Amgen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06660173 | Nov 2024 → Oct 2025 overdue | type 2 diabetes mellitus | Amgen | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05669599 | Jan 2023 → Oct 2024 | obesity disorder, type 2 diabetes mellitus | Amgen | Completed | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07866066 | Nov 2026 → Sep 2028 expected | type 2 diabetes mellitus | Amgen | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07684144 | Jul 2026 → Dec 2027 expected | obesity disorder, type 2 diabetes mellitus | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT07684235 | Jul 2026 → Dec 2027 expected | obesity disorder | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT07575399 | May 2026 → Jan 2028 expected | obesity disorder | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT07225686 | Dec 2025 → Aug 2027 expected | obesity disorder, obstructive sleep apnea syndrome | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07226765 | Nov 2025 → Aug 2027 expected | obstructive sleep apnea syndrome | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT07037433 | Jul 2025 → Jun 2028 expected | atherosclerotic cardiovascular disease, obesity disorder | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT07037459 | Jun 2025 → Jun 2028 expected | diastolic heart failure, mild heart failure, obesity disorder | Amgen | Recruiting | No outcome recorded |
| Phase 3 | NCT06987695 | Jun 2025 → Apr 2027 expected | obesity disorder | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06858878 | Mar 2025 → Jan 2027 expected | type 2 diabetes mellitus | Amgen | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06858839 | Mar 2025 → Jan 2027 expected | obesity disorder | Amgen | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-06-23 | Amgen | Results RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS amgen.com ↗
Amgen (NASDAQ:AMGN) today announced full results from Part 1 of the Phase 2 study of MariTide (maridebart cafraglutide, formerly AMG 133), a long-acting, peptide-antibody conjugate subcutaneously administered monthly or less frequently. |
| 2025-06-18 | Amgen | Results AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS amgen.com ↗
The Symposium will highlight 52-week efficacy, safety and tolerability data from Part 1 of the Phase 2 study, complete data from the primary analysis of the Phase 1 pharmacokinetics low dose initiation (PK-LDI) study, and additional information on the Phase 3 MARITIME Chronic Weight Management studies. |
| 2024-11-26 | Amgen | Results AMGEN ANNOUNCES ROBUST WEIGHT LOSS WITH MARITIDE IN PEOPLE LIVING WITH OBESITY OR OVERWEIGHT AT 52 WEEKS IN A PHASE 2 STUDY amgen.com ↗
Amgen (NASDAQ:AMGN) today announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide (maridebart cafraglutide, formerly AMG 133), an investigational antibody peptide conjugate subcutaneously administered monthly or less frequently. |
| 2024-11-13 | Amgen | Results AMGEN PROVIDES STATEMENT ON MARITIDE PHASE 1 DATA amgen.com ↗
The Phase 1 study results do not suggest any bone safety concern or change our conviction in the promise of MariTide. |
| 2022-12-01 | Amgen | Results AMGEN PRESENTS NEW AMG 133 PHASE 1 CLINICAL DATA AT WCIRDC 2022 amgen.com ↗
The MAD cohorts showed mean percent changes in body weight (BW), ranging from -7.2% at the lowest dose (140mg Q4W), to -14.5% at the highest dose (420mg Q4W) by day 85. |
All press releases naming this drug 5 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 23 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Maridebart Cafraglutide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07037433 ↗ |
| Known as | AMG 133 | “Maridebart Cafraglutide (AMG 133)” NCT07523711 ↗ |
| Known as | Maridebart cafraglutida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314751 ↗ |
| Route | Subcutaneous | “by subcutaneous (SC) injection.” NCT05669599 ↗ |